Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Terminated

Beckman Coulter Lipase, REF OSR6130 and OSR6230.

FDA Recall Z-0210-2020 · Posted None

Recalling FirmBeckman Coulter Inc.
Recall StatusTerminated
Product CodeCDT
Date Initiated2018-08-24
Date Terminated2024-08-02
Product Quantity20,926 units

Reason for Recall

NAPQI, a metabolite of Acetaminophen, causes negative interference with the recalled product assays at levels present in the serum/plasma of overdose patients.

Firm Action

The recalling firm issued letters dated 8/21/2018 via email or postal mail if an email address was not available on 8/24/2018 to their customers. The letter identified the affected product, problem and actions to be taken. For questions call 1-800-223-0139 in the United States and Canada. Outside the United States and Canada contact local Beckman Coulter Representative.

Root Cause

Nonconforming Material/Component

Distribution Pattern

Distribution was nationwide. There was government and military distribution. Foreign distribution was made to Canada.

Official Source

View FDA Recall →

Source: FDA Enforcement Report / Recall database. Always confirm against the official FDA record.

↑